Kusurinomadoguchi (5592) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
8 Sep, 2025Executive summary
Achieved record-high quarterly revenue and operating profit, driven by strong performance in media and core system businesses, with operating profit reaching initial full-year targets a quarter early.
Net income attributable to parent increased 117% year-over-year for the nine-month period, with EBITDA up 37%.
Absorbed a wholly owned subsidiary in November, resulting in a large deferred tax benefit and boosting net profit.
Strategic focus on expanding recurring (stock) revenue across all business lines.
Financial highlights
Consolidated revenue for Q3 was ¥8,420 million, up 35% year-over-year; operating profit was ¥1,556 million, up 41%.
Q3 alone saw revenue of ¥2,976 million (+49% YoY), operating profit of ¥606 million (+134% YoY), and net profit of ¥1,004 million (+430% YoY).
EBITDA for the nine-month period reached ¥2,463 million (+37% YoY).
Gross profit margin improved, with gross profit at ¥5,002 million (+40% YoY) and gross margin for the nine-month period at 59%.
Operating margin for Q3 reached 20%.
Outlook and guidance
Full-year guidance raised: revenue expected at ¥10,500 million (+20% YoY), operating profit at ¥1,800 million (+31% YoY), and net profit at ¥1,690 million (+94% YoY).
Year-end dividend forecast increased from ¥15.40 to ¥22.63 per share.
Medium-term plan targets ¥20 billion in recurring revenue and over ¥5 billion in operating profit by FY2030.
Latest events from Kusurinomadoguchi
- Record profit and revenue growth drive higher guidance and dividend, fueled by digital healthcare and acquisitions.5592
Q3 202613 Feb 2026 - Record profit and net income driven by recurring sales growth and capital reduction effects.5592
Q2 202614 Nov 2025 - Q1 FY2025 revenue up 22.1% YoY, but profit fell due to higher SG&A from acquisitions.5592
Q1 20258 Sep 2025 - Revenue up 28% YoY, profit growth, digital healthcare demand, and guidance maintained.5592
Q2 20258 Sep 2025 - Strong profit and revenue growth, improved financials, and robust digital healthcare outlook.5592
Q4 20258 Sep 2025 - Record Q1 revenue and profit growth with strong margins; full-year guidance unchanged.5592
Q1 20268 Sep 2025